INBRX-106

INBRX-106 is a monoclonal antibody developed by Inhibrx Biosciences. The sponsor describes its target as OX40, which OnCo does not yet have a target page for. The sponsor states: A hexavalent OX40 agonist antibody designed to promote hyperclustering of OX40, giving more potent activation of the OX40 costimulatory pathway than traditional Fc-crosslinking-dependent bivalent OX40 antibodies. ClinicalTrials.gov describes the intervention as: INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06295731 (INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC), in head and neck squamous cell carcinoma. The largest, NCT06295731, plans to enrol 410 participants with primary completion expected 2029-05. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.